Awstralja - Ingliż - APVMA (Australian Pesticides and Veterinary Medicines Authority)

nufarm australia limited - chlorothalonil - fungicide - almond | apricot | banana | broad bean | broccoli | brussels sprouts | cabbage | capsicum or pepper | carrot | cauliflower | cel - alternaria leaf spot - alternaria spp. | anthracnose | anthracnose on cucurbit | ascochyta blight or black stem on pea | ascochyta leaf spot - ascochyta rhei | belly rot | black spot - mycosphaerella pinodes | black spot on grapes - elsinoe ampelina | blossom blight - monilinia laxa | botrytis | brown fruit rot - monilinia fructicola | brown patch - rhizoctonia spp. | bunch rot | cercospora leaf spot | chocolate spot on bean | collar black spot rot on pea | dollar spot | downy mildew on allium (onion, garlic) | downy mildew on cucurbit | downy mildew on grape | downy mildew on pea | early blight on celery | early blight or target blackspot | early leaf spot on peanut | freckle or scab on stone fruit | grey leaf spot - stemphylium solani | grey mould - botrytis cinerea | gummy stem blight - didymella bryoniae | late blight or irish blight | late leaf spot on peanut | leaf blight - alternaria cucumerina | leaf blight - alternaria dauci | leaf curl | leaf mould of tomato | leaf speckle on banana | leaf spot | le

Stati Uniti - Ingliż - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - rosuvastatin calcium (unii: 83mvu38m7q) (rosuvastatin - unii:413kh5zj73) - rosuvastatin 10 mg - crestor is indicated as adjunctive therapy to diet to reduce elevated total-c, ldl-c, apob, nonhdl‑c, and triglycerides and to increase hdl‑c in adult patients with primary hyperlipidemia or mixed dyslipidemia. lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and nonpharmacological interventions alone has been inadequate. pediatric patients 10 to 17 years of age with heterozygous familial hypercholesterolemia (hefh) adjunct to diet to reduce total‑c, ldl‑c and apob levels in adolescent boys and girls, who are at least one year post-menarche, 10‑17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: ldl‑c > 190 mg/dl or > 160 mg/dl and there is a positive family history of premature cardiovascular disease (cvd) or two or more other cvd risk factors. crestor is indicated as adjunctive therapy to diet for the treatment of adult patients with hypertrig

Stati Uniti - Ingliż - NLM (National Library of Medicine)

biocon pharma inc - rosuvastatin calcium (unii: 83mvu38m7q) (rosuvastatin - unii:413kh5zj73) - rosuvastatin 5 mg - pediatric use information for patients 7 to 17 years of age is approved for astrazeneca’s crestor (rosuvastatin calcium) tablets. however, due to astrazeneca’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. rosuvastatin tablets are indicated as adjunctive therapy to diet for the treatment of adult patients with hypertriglyceridemia. rosuvastatin tablets are indicated as an adjunct to diet for the treatment of adult patients with primary dysbetalipoproteinemia (type iii hyperlipoproteinemia). rosuvastatin tablets are indicated as adjunctive therapy to other lipid-lowering treatments (e.g., ldl apheresis) or alone if such treatments are unavailable to reduce ldl-c, total-c, and apob in adult patients with homozygous familial hypercholesterolemia. rosuvastatin tablets have not been studied in fredrickson type i and v dyslipidemias. rosuvastatin tablets are contraindicated in the following conditions: - patients with a known hypersensitivity to any component of thi

Stati Uniti - Ingliż - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - rosuvastatin calcium (unii: 83mvu38m7q) (rosuvastatin - unii:413kh5zj73) - pediatric use information for patients 7 to 17 years of age is approved for astrazeneca’s crestor (rosuvastatin calcium) tablets. however, due to astrazeneca’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. rosuvastatin calcium tablets are indicated as adjunctive therapy to diet for the treatment of adult patients with hypertriglyceridemia. rosuvastatin calcium tablets are indicated as an adjunct to diet for the treatment of adult patients with primary dysbetalipoproteinemia (type iii hyperlipoproteinemia). rosuvastatin calcium tablets are indicated as adjunctive therapy to other lipid-lowering treatments (e.g., ldl apheresis) or alone if such treatments are unavailable to reduce ldl-c, total-c, and apob in adult patients with homozygous familial hypercholesterolemia. rosuvastatin calcium tablets have not been studied in fredrickson type i and v dyslipidemias. rosuvastatin calcium tablets are contraindicated in the following conditions: - patients with a known

Stati Uniti - Ingliż - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - rosuvastatin calcium (unii: 83mvu38m7q) (rosuvastatin - unii:413kh5zj73) - pediatric use information for patients 7 to 17 years of age is approved for astrazeneca’s crestor (rosuvastatin calcium) tablets. however, due to astrazeneca’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. rosuvastatin is indicated as adjunctive therapy to diet for the treatment of adult patients with hypertriglyceridemia. rosuvastatin is indicated as an adjunct to diet for the treatment of adult patients with primary dysbetalipoproteinemia (type iii hyperlipoproteinemia). rosuvastatin is indicated as adjunctive therapy to other lipid-lowering treatments (e.g., ldl apheresis) or alone if such treatments are unavailable to reduce ldl-c, total-c, and apob in adult patients with homozygous familial hypercholesterolemia. rosuvastatin has not been studied in fredrickson type i and v dyslipidemias. rosuvastatin is contraindicated in the following conditions: •           patients with a known hypersensitivity to any component of this product. hypersensitivity reactio

Stati Uniti - Ingliż - NLM (National Library of Medicine)

lifestar pharma llc - rosuvastatin calcium (unii: 83mvu38m7q) (rosuvastatin - unii:413kh5zj73) - pediatric use information for patients 7 to 17 years of age is approved for astrazeneca's crestor (rosuvastatin calcium) tablets. however, due to astrazeneca's marketing exclusivity rights, this drug product is not labeled with that pediatric information. rosuvastatin tablets are indicated as adjunctive therapy to diet for the treatment of adult patients with hypertriglyceridemia. rosuvastatin tablets are indicated as an adjunct to diet for the treatment of adult patients with primary dysbetalipoproteinemia (type iii hyperlipoproteinemia). rosuvastatin tablets are indicated as adjunctive therapy to other lipid-lowering treatments (e.g., ldl apheresis) or alone if such treatments are unavailable to reduce ldl-c, total-c, and apob in adult patients with homozygous familial hypercholesterolemia. rosuvastatin tablets have not been studied in fredrickson type i and v dyslipidemias.  rosuvastatin tablets are contraindicated in the following conditions: - patients with a known hypersensitivity to any component of th

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - rosuvastatin (as calcium) - film coated tablet - 15 milligram

Iżrael - Ingliż - Ministry of Health

medison pharma ltd - tipiracil as hydrochloride; trifluridine - film coated tablets - tipiracil as hydrochloride 6.14 mg; trifluridine 15 mg - trifluridine, combinations - colorectal cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti-egfr agents.gastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.

Iżrael - Ingliż - Ministry of Health

medison pharma ltd - tipiracil as hydrochloride; trifluridine - film coated tablets - tipiracil as hydrochloride 6.14 mg; trifluridine 15 mg - trifluridine, combinations - colorectal cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti-egfr agents.gastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.

Stati Uniti - Ingliż - NLM (National Library of Medicine)

sandoz inc - nafcillin sodium (unii: 49g3001bck) (nafcillin - unii:4cnz27m7rv) - nafcillin 1 g - nafcillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. culture and susceptibility tests should be performed initially to determine the causative organism and its susceptibility to the drug (see clinical pharmacology: susceptibility testing ). nafcillin should not be used in infections caused by organisms susceptible to penicillin g. if the susceptibility tests indicate that the infection is due to methicillin-resistant staphylococcus sp., therapy with nafcillin for injection should be discontinued and alternative therapy provided. to reduce the development of drug-resistant bacteria and maintain the effectiveness of nafcillin for injection and other antibacterial drugs, nafcillin for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selec